parallel randomized trial
S003430
Design
Conduct and analysis
Arms
| Arm | Treatment | Background | Randomized | Analyzed | Completed treatment |
|---|---|---|---|---|---|
| A1 | Liraglutide 3.0 mg subcutaneous once daily Liraglutide 3.0 mg/day plus escitalopram | escitalopram 20 mg once daily; lifestyle: not reported | |||
| A2 | Placebo Placebo plus escitalopram | escitalopram 20 mg once daily; lifestyle: not reported |
Baseline characteristics
As printed in the trial reports or registry, per arm or for the whole trial.
| Characteristic | Statistic | Liraglutide 3.0 mg subcutaneous once daily A1 | Placebo A2 | Whole trial ALL |
|---|---|---|---|---|
| age | mean (years) | 41.2 | ||
| age | sd (years) | 12.6 | ||
| bmi | mean (kg/m2) | 33.9 | ||
| bmi | sd (kg/m2) | 11.8 | ||
| female | percent | 60 |
Results
2 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
Percent body weight change (2 lines; O10)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| 6 | A1 | percent change | -3.2 percent | 1.0 | not stated; other; R0042455:p1 | ||
| 6 | A2 | percent change | -0.2 percent | 0.1 | not stated; other; R0042455:p1 |